Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States

Clinical Cardiology

Volumn 33, Issue 5, 2010, Pages 270-279

  Naccarelli, Gerald V ^a   Johnston, Stephen S ^b   Lin, Jay ^c   Patel, Parag P ^a   Schulman, Kathy L ^b  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b Thomson Reuters   (United States)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; DRONEDARONE; WARFARIN;

ACUTE CORONARY SYNDROME; AGED; ARTERY EMBOLISM; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SURGERY; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; DATA BASE; DIABETES MELLITUS; DRUG EFFICACY; EMPLOYER; FATALITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEALTH INSURANCE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DEATH; HEART DISEASE; HEART INFARCTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HOSPITAL PATIENT; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; HYPERTENSION; HYPOTENSION; LUNG DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; PACEMAKER; RETROSPECTIVE STUDY; STABLE ANGINA PECTORIS; STROKE; SYNCOPE; TRANSIENT ISCHEMIC ATTACK; UNITED STATES; VALVULAR HEART DISEASE; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CONTROLLED CLINICAL TRIALS AS TOPIC; COST SAVINGS; DATABASES AS TOPIC; DRUG COSTS; FEMALE; HOSPITAL COSTS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INPATIENTS; MALE; MEDICARE PART B; MODELS, ECONOMIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77953168894     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20759     Document Type: Article

References (42)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
2. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104:1534-1539.
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence [published correction appears in Circulation. 2006;114:e498]. Circulation. 2006;114:119-125.
4. Miyasaka Y, Barnes ME, Gersh BJ, et al. Changing trends of hospital utilization in patients after their first episode of atrial fibrillation. Am J Cardiol. 2008;102:568-572.
5. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials [published correction appears in Arch Intern Med. 1994;154:2254]. Arch Intern Med. 1994;154:1449-1457.
6. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995;98:476-484.
7. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113:359-364.
8. Halligan SC, Gersh BJ, Brown RD, Jr., et al. The natural history of lone atrial flutter. Ann Intern Med. 2004;140:265-268.
9. Biblo LA, Yuan Z, Quan KJ, et al. Risk of stroke in patients with atrial flutter. Am J Cardiol. 2001;87:346-349, A9.
10. Reynolds MR, Essebag V, Zimetbaum P, et al. Health care resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol. 2007;18:628-633.
11. Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9:348-356.
12. Le Heuzey JY, Paziaud O, Piot O, et al. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J. 2004;147:121-126.
13. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48:854-906.
14. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation. 2003;108:711-716.
15. Friberg J, Buch P, Scharling H, et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology. 2003;14:666-672.
16. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678.
17. Ye X, Gross CR, Schommer J, et al. Initiation of statins after hospitalization for coronary heart disease. J Manag Care Pharm. 2007;13:385-396.
18. Zhou F, Harpaz R, Jumaan AO, et al. Impact of varicella vaccination on health care utilization. JAMA. 2005;294:797-802.
19. Hohnloser SH, Connolly SJ, Crijns HJ, et al. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol. 2008;19:69-73.
20. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687.
21. Tu JV, Zhang H. Congestive heart failure outcomes in Ontario. In: Naylor CD, Slaughter PM, eds. Cardiovascular Health and Services in Ontario: An ICES Atlas. Toronto, Canada: Institute for Clinical Evaluative Sciences; 1999; 30-33.
22. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-e181.
23. Centers for Medicare & Medicaid Services, US Department of Health and Human Services. Health Care Financing Review: Medicare & Medicaid Statistical Supplement. Table 5.5: Discharges, total days of care, and program payments for Medicare beneficiaries discharged from short-stay hospitals, by principal diagnoses with major diagnostic classifications (MDCs): calendar year 2006. Baltimore, MD: Centers for Medicare & Medicaid Services; 2006.
24. Brüggenjürgen B, Rossnagel K, Roll S, et al. The impact of atrial fibrillation on the cost of stroke: the Berlin Acute Stroke Study. Value Health. 2007;10:137-143.
25. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998;158:229-234.
26. Kim MH, Lin J, Hussein M, et al. How much does it cost to manage atrial fibrillation in the United States? Circ Cardiovasc Qual Outcomes. 2009;2:e1-e66.
27. de Lissovoy G, Zodet M, Coyne K, et al. Treatment charges and resource use among patients with heart failure enrolled in an MCO. Manag Care Interface. 2002;15:46-52.
28. Claesson L, Gosman-Hedström G, Johannesson M, et al. Resource utilization and costs of stroke unit care integrated in a care continuum: a 1-year controlled, prospective, randomized study in elderly patients: the Göteborg 70+ Stroke Study. Stroke. 2000;31:2569-2577.
29. Heller RF, Fisher JD, D'Este CA, et al. Death and readmission in the year after hospital admission with cardiovascular disease: the Hunter Area Heart and Stroke Register. Med J Aust. 2000;172:261-265.
30. Johansen HL, Wielgosz AT, Nguyen K, et al. Incidence, comorbidity, case fatality and readmission of hospitalized stroke patients in Canada. Can J Cardiol. 2006;22:65-71.
31. Aranda JM, Jr., Johnson JW, Conti JB. Current trends in heart failure readmission rates: analysis of Medicare data. Clin Cardiol. 2009;32:47-52.
32. Kim MH, Lin J, Hussein M, et al. Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. Curr Med Res Opin. 2009;25:1215-1220.
33. Humphries KH, Jackevicius C, Gong Y, et al. Population rates of hospitalization for atrial fibrillation/flutter in Canada. Can J Cardiol. 2004;20:869-876.
34. De Ferrari GM, Klersy C, Ferrero P, et al. Atrial fibrillation in heart failure patients: prevalence in daily practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail. 2007;9:502-509.
35. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythmcontrol in patients with atrial fibrillation.N Engl J Med. 2002;347:1825-1833.
36. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509-1513.
37. Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, et al. Antiar-rhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719-728.
38. Wyse DG, Slee A, Epstein AE, et al. Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm. 2004;1: 531-537.
39. Slee A, Rathod S, Saksena S. Impact of a composite outcome analysis in evaluating atrial fibrillation treatment strategies: a current reassessment of the AFFIRM study. Circulation. 2009;120:S692 (abstract).
40. Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341: 857-865.
41. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40: 373-383.
42. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.